Hellllooooo 2022! The Alturas Analytics team is primed and excited for what you have in store!
Reflecting on 2021, I am truly humbled to work with this dedicated group of professionals who define “The Alturas Way” through teamwork, selflessness, philanthropic giving, and volunteerism. The Alturas team continues to showcase agility and flexibility by delivering the superior service our clients expect while carefully balancing surges in workload and implementation of novel techniques.
I am exceptionally proud of the collaborations, completed studies, and record-setting growth we experienced. At the core of our success are the relationships we develop between our clients and ourselves.
The Industry
The evolution of cell and gene therapies is progressing at a heightened pace. In response, we have adapted our approach and methodologies to answer the bioanalytical challenges this presents. Microflow, automation, and hybrid LBA-LC-MS/MS are fully integrated into our workflow and are part of routine services offered in our expanding portfolio. Involvement in biomarker analysis has further broadened our influence in these new market sectors. Support of small molecule development continues to grow and diversify, including GC-MS/MS of volatile compounds and microsample techniques in response to the migration to patient-centric and at-home sample collection.
Our People. Our Future.
We are investing in Alturas’ future not only with the expansion of our physical infrastructure but with the leadership development of our most important resource: our people. Leadership empowers others, encourages strategic thinking, and fosters innovation that will impact the pharmaceutical industry and usher technology forward. We take great pride in recognizing individual potential and developing the skills needed to become a successful member of the Alturas team.
It is with deep gratitude we acknowledge our clients, partners, and colleagues who made 2021 a successful year. As we soar into 2022, we welcome new opportunities to work with all stakeholders in bringing life-saving therapies to patients.
Warm Regards,
Robin Woods
